Samsung Biologics to Acquire PolyPeptide in $1.8 Billion All-Cash Deal
Samsung Biologics has agreed to acquire PolyPeptide Group, a Swiss contract drugmaker, in an all-cash deal valuing the target at 1.46 billion Swiss francs ($1.8 billion), expanding its manufacturing capabilities.
From the sources (6 posts)
@reutersSamsung Biologics to launch $1.8 billion all-cash bid for PolyPeptide
@l2presearchSamsung Biologics announces all-cash offer to acquire PolyPeptide, accelerating multi-modality strategy and expanding global network across U.S., Europe, and India
@businessSamsung Biologics has agreed to acquire Switzerland’s PolyPeptide in an all-cash deal that values the contract drugmaker’s equity at about 1.46 billion Swiss francs ($1.8 billion), expanding its manufacturing capabilities
@cnbcSamsung Biologics to acquire Switzerland's PolyPeptide Group in $1.8 billion all-cash deal
@firstsquawkSamsung Biologics to launch $1.8 bn bid for Swiss PolyPeptide - NA
@reutersSamsung Biologics to launch $1.8 billion all-cash bid for PolyPeptide